	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M PR	12M PR	12M AR	12M PRESS
Total Revenue	4,717	5,049	6,056	5,855	5,986	6,658	7,896	9,204
Cost of Operating Revenue	2,153	2,451	2,950	2,575	2,629	2,908	3,669	4,072
Gross Profit	2,564	2,597	3,106	3,280	3,357	3,750	4,227	5,131
Gross Margin	54.4	51.4	51.3	56.0	56.1	56.3	53.5	55.8
Total Operating Expenses	4,232	4,657	5,148	4,770	5,064	5,741	6,811	7,830
Operating Profit	485	391	909	1,085	921	917	1,085	1,374
Operating Margin	10.3	7.7	15.0	18.5	15.4	13.8	13.7	14.9
Financing Income/(Expense) - Net	-203	-208	-176	-129	-183	-201	-156	-25
Profit before Taxes	323	105	657	973	747	727	971	1,287
Income Taxes	120	5	239	270	185	200	264	346
Profit after Tax	189	84	392	662	532	498	681	924
PAT Margin	4.0	1.7	6.5	11.3	8.9	7.5	8.6	10.0
EPS - Basic - ex Extraordinary Items	10.01	4.42	20.74	35.02	28.13	26.35	36.43	48.77
EPS - Diluted - ex Extraordinary Items	10.01	4.42	20.74	35.02	28.13	26.35	36.43	48.77
EBIT	485	391	909	1,085	921	917	1,085	1,374
EBITDA	785	712	1,232	1,330	1,182	1,230	1,469	1,789
EBITDA Margin	16.6	14.1	20.3	22.7	19.7	18.5	18.6	19.4

Balance Sheet

Abridged

Understanding Balance Sheet

Emcure Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	PR	PR	PR	AR	PRESS
Total Current Assets	2,453	2,703	3,717	3,424	3,836	4,260	4,556	5,612
Long-Term Investments	8	13	8	46	58	20	22	61
Property Plant & Equipment - Net	2,077	1,974	1,933	1,985	2,215	2,397	2,427	2,491
Total Non-Current Assets	3,357	3,301	3,090	2,639	2,837	3,546	3,677	4,000
Total Assets	5,810	6,004	6,807	6,063	6,673	7,806	8,233	9,612
Total Current Liabilities	2,571	2,920	3,408	2,965	3,019	3,210	2,668	3,912
Long Term Debt	837	681	821	829	859	982	447	514
Total Non-Current Liabilities	1,346	1,100	1,031	984	1,004	1,474	923	724
Total Liabilities	3,916	4,020	4,439	3,949	4,023	4,684	3,591	4,636
Total Shareholders' Equity	1,829	1,912	2,273	1,988	2,501	2,952	4,446	4,950
Minority Interest	65	72	95	127	149	169	195	27
Total Equity	1,894	1,984	2,368	2,114	2,650	3,122	4,642	4,977
Total Liabilities & Equity	5,810	6,004	6,807	6,063	6,673	7,806	8,233	9,612

Cash Flow

Abridged

Understanding Cash Flow Statement

Emcure Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M PR	12M PR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	435	423	862	911	866	856	1,170	1,381
Working Capital - Increase/(Decrease)	-149	-124	-335	-292	-292	51	-424	-530
Net CF from Operating Activities	286	299	528	619	574	907	746	851
Capital Expenditures - Net	405	138	133	394	402	296	376	543
Net CF from Investing Activities	-411	-165	-259	-795	-473	-730	-117	-1,195
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	57
Stock - Issuance/(Retirement) - Net	-	-	-18	-	-	-13	779	7
Debt - LT & ST - Issuance/(Retirement) - Total	-474	-34	25	66	78	119	-1,465	488
Net Cash Flow from Financing Activities	-574	-98	-4	3	33	44	-685	438
Free Cash Flow to Equity	-594	127	419	291	249	730	-1,095	796
Free Operating CF net dividend	-131	145	382	222	170	600	339	246
Free Operating CF	-131	145	382	222	170	600	339	303

Business Segment Analysis

FY End:

Mar 25

Emcure Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 406.93 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 7,896.00 Cr

Assets

Pharmaceuticals (100.0%)₹ 8,232.72 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 1,084.73 Cr

Regional Segment Analysis

FY End:

Mar 25

Emcure Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (46.3%)₹ 3,659.28 CrEurope (19.3%)₹ 1,525.47 CrOther continents (17.9%)₹ 1,414.51 CrNorther America (16.4%)₹ 1,296.74 Cr

Historical Segment Analysis

Track how Emcure Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	417	155	146	397	403	307	407

Frequently Asked Questions

What is the revenue of Emcure Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Emcure Pharmaceuticals Ltd. is ₹ 9,203.54 Cr, reflecting a 1-year growth of 16.56% and a 3-year CAGR of 15.42%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Emcure Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Emcure Pharmaceuticals Ltd. is ₹ 924.36 Cr, with a 3-year earnings CAGR of 20.13%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Emcure Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Emcure Pharmaceuticals Ltd. is approximately ₹ 1,373.56 Cr (based on an operating margin of 14.92%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Emcure Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Emcure Pharmaceuticals Ltd. is 48.77. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Emcure Pharmaceuticals Ltd.?

The debt-to-equity ratio of Emcure Pharmaceuticals Ltd. stands at 0.31. The interest coverage ratio is 9.56x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Emcure Pharmaceuticals Ltd.?

The estimated book value per share of Emcure Pharmaceuticals Ltd. is 260.97 (derived from a P/B ratio of 6.83 and market price of ₹ 1,783.20), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Emcure Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Emcure Pharmaceuticals Ltd. is ₹ 850.53 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Emcure Pharmaceuticals Ltd. report consolidated or standalone financials?

Emcure Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.